1. Australia Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Holista Colltech Limited

Holista Colltech Limited

AASX:HCT
0.04
AUD
+0.00
(-11.36%)
0.00EPS
31.63MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
0.04
0.05
0.04
0.04
0.04
0.04
0.04
0.03
0.03
0.03
0.02
0.02
0.02
Basic EPS, GAAP
-0.01
-0.02
- -
- -
-0.02
-0.01
- -
-0.02
- -
-0.01
-0.01
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.01
0.01
0.02
- -
0.02
0.02
0.02
0.02
0.01
0.01
- -
-0.01
- -
Tangible Book Value per Share
0.01
0.01
0.01
- -
0.01
0.02
0.02
0.02
0.01
0.01
- -
-0.01
- -
Basic Weighted Avg Shares
130
136
151
160
179
207
207
269
273
279
279
281
331
Sales/Revenue/Turnover
5
6
7
6
8
8
7
7
8
8
6
6
6
Operating Margin (%)
-22.43
-42.49
-1.51
-14.76
-44.57
-22.78
-16.6
-63.95
-15.53
-17.19
-50.23
3.48
-29.01
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-2
-3
- -
- -
-3
-2
-1
-5
-1
-1
-2
- -
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
250.21
- -
Profit Margin (%)
-30.79
-53.1
0.49
-6.51
-39.23
-21.88
-7.88
-76.55
-15.66
-17.63
-38.06
-1.5
-16.46
Working Capital
1
2
2
- -
1
2
1
3
2
1
-1
-4
-1
LT Debt
4
3
1
1
1
1
1
1
1
1
1
- -
- -
Total Equity
2
1
2
- -
3
4
4
4
3
2
-1
-3
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
59.35
- -
Return on Common Equity (%)
-63.1
-192.36
1.66
- -
- -
-40.23
-11.93
-114.03
-27.72
-41.95
-133.16
- -
- -

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-3.81%
-87.59%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
97.77%
185.01%
1,026.8%
Sales/Revenue/Turnover
-0.76%
-3.02%
2.96%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
6
2024
- -
- -
6
2025
- -
- -
6

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.01
2024
- -
- -
- -
2025
- -
- -
- -

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Man Loong Leong
Full Time Employees
3
Sector
Health technology
Industry
Biotechnology
Address
283 Rokeby Road Subiaco WA Australia 6008
IPO Date
Feb 26, 2004
Website
holistaco.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Holista CollTech Limited (ASX: HCT) develops and commercializes innovative natural health solutions derived from colostrum, a nutrient-rich first milk produced by mammals post-parturition. The company offers a portfolio of proprietary products including ColoBoost for immune support and general wellness; Lactoferrin for iron absorption, antimicrobial properties, and gut health; GMP-grade colostrum powder for dietary supplements and functional foods; and lipid-based microencapsulation technologies for enhanced bioavailability of bioactives. Holista CollTech also provides contract manufacturing services for nutraceuticals and natural extracts, along with research and development collaborations focused on colostrum-derived therapeutics for conditions such as inflammatory bowel disease and viral infections. Founded in 2001 and headquartered in Subiaco, Australia, the company operates primarily in the nutraceuticals and biotechnology sectors, targeting health-conscious consumers, dietary supplement manufacturers, and pharmaceutical partners in Australia, Southeast Asia, Europe, and North America. Its business segments encompass colostrum processing, product innovation, and bioencapsulation services, with key facilities in Australia and Malaysia supporting global distribution. In the past two years, Holista CollTech has pursued strategic expansions including a 2024 research partnership with an Australian university to advance colostrum-based antivirals; completion of a A$2.5 million capital raise in late 2024 to fund GMP facility upgrades and clinical trials; and the launch of a new line of vegan-friendly colostrum alternatives in early 2025 targeting the plant-based wellness market. The company also restructured its Malaysian subsidiary in 2025 to streamline export operations amid rising demand in Asia-Pacific, marking a shift toward greater emphasis on international contract development and manufacturing organization (CDMO) services.